Screening Platform for Clinical Trials in Advanced Colorectal Cancer
NCT ID: NCT01723969
Last Updated: 2022-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
668 participants
OBSERVATIONAL
2013-09-30
2020-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Currently some of the most challenging clinical questions arise from the molecular sub-division of CRC that would theoretically allow to inhibit the specific, altered pathways in the patients.
A major problem for trials in this "personalized medicine" is that the low frequency of the different mutations requires a high effort for screening and identifying the patients.
The EORTC CRC screening platform will hopefully offer a feasible and efficient way to characterize the patients on the molecular basis of their tumors and allow to offer them rapid and preferential participation in clinical studies with new drugs targeted to their specific pathway alterations.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Comparative Study Between Early Onset Colorectal Cancer and Late Onset Colorectal Cancer Patients
NCT06326879
Earlier Detection and Optimization of Treatment and Prognosis for Patients With Early-onset Colorectal Cancer
NCT06568679
Prospective Data Collection Initiative on Colorectal Cancer
NCT02070146
Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast
NCT03789162
Colorectal Cancer: Screening vs. Non-Screening
NCT02727894
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Colo-rectal cancer
Tumour markers testing in patients with advanced or metastatic colo-rectal cancer
Tumour markers testing
Tumour markers testing in patients advanced or metastatic colo-rectal cancer.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tumour markers testing
Tumour markers testing in patients advanced or metastatic colo-rectal cancer.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gunnar Folprecht, MD
Role: STUDY_CHAIR
Universitaetsklinikum Carl Gustav Carus, Dresden, DE
Sabine Tejpar, MD, PhD
Role: STUDY_CHAIR
U.Z. Leuven - Campus Gasthuisberg, Leuven, BE
Daniela Aust, MD
Role: STUDY_CHAIR
Universitaetsklinikum Carl Gustav Carus, Dresden, DE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet
Brussels, , Belgium
Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme
Brussels, , Belgium
Cliniques Universitaires Saint-Luc
Brussels, , Belgium
Universitair Ziekenhuis Antwerpen
Edegem, , Belgium
U.Z. Leuven - Campus Gasthuisberg
Leuven, , Belgium
Bank Of Cyprus Oncology Centre
Stróvolos, , Cyprus
Gustave Roussy Cancer Campus
Villejuif, , France
Universitaetsklinikum Carl Gustav Carus
Dresden, , Germany
Universitaets-Krankenhaus Eppendorf
Hamburg, , Germany
Universitaetsklinikum Leipzig
Leipzig, , Germany
Ludwig-Maximilians-Universitaet Muenchen - Klinikum der Universitaet Muenchen - Campus Grosshadern
München, , Germany
Kliniken Oldenburg
Oldenburg, , Germany
University General Hospital Heraklion
Heraklion, , Greece
IRCCS Azienda Ospedaliera Universitaria San Martino "IST" Istituto Nazionale per la Ricerca sul Cancro
Genova, , Italy
Seconda Universita Degli Studi Di Napoli
Napoli, , Italy
The Great Poland Cancer Centre
Poznan, , Poland
Maria Sklodowska-Curie Memorial Cancer Centre
Warsaw, , Poland
I.P.O. Francisco Gentil - Centro De Lisboa
Lisbon, , Portugal
Hospital General Vall D'Hebron
Barcelona, , Spain
Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals
L'Hospitalet de Llobregat, , Spain
Hospital Universitario San Carlos
Madrid, , Spain
Hospital Universitario 12 De Octubre
Madrid, , Spain
Ostra Sjukhuset
Gothenburg, , Sweden
Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie
Geneva, , Switzerland
Centre Hospitalier Universitaire Vaudois
Lausanne, , Switzerland
Hopital du Valais - Hopital de Sion
Sion, , Switzerland
UniversitaetsSpital Zurich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-003714-14
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
EORTC-40CRC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.